Hib meningococcal group C vaccine - GlaxoSmithKline

Drug Profile

Hib meningococcal group C vaccine - GlaxoSmithKline

Alternative Names: Hib-MenC conjugated vaccine - GlaxoSmithKline; Hib-MenC vaccine - GSK Biologicals; Hib-MenC-TT; Hib-MenC-TT conjugated vaccine - GlaxoSmithKline; HibMenC; Menitorix

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Haemophilus vaccines; Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemophilus infections; Meningococcal group C infections

Most Recent Events

  • 01 Nov 2012 GlaxoSmithKline completes a phase III trial in Haemophilus infections and Meningococcal group C infections (prevention, in treatment-experienced children) in Germany, Poland and Spain (NCT00891176)
  • 19 Feb 2010 GlaxoSmithKline completes a phase III trial evaluating its immunogenicity and safety in preterm infants in Spain
  • 18 Aug 2006 First global launch of Menitorix™ in the United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top